Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – could be dealing with competition from A better-to-dose alternate from Sling Therapeutics. The money will aid a Phase 2b clinical trial assessing the corporation